Compass pathways stock forecast.

In the last 3 months, 5 analysts have offered 12-month price targets for Compass Pathways. The company has an average price target of $50.6 with a high of $120.00 and a low of $19.00. Below is a ...WebIt is one of the best psychedelic stocks to invest in. On December 15, EF Hutton analyst Elemer Piros initiated coverage of COMPASS Pathways plc (NASDAQ:CMPS) with a Buy rating and a $38 price target.COMPASS Pathways (CMPS) Stock Forecast & Price Target $6.05 +0.22 (+3.77%) (As of 11/22/2023 ET) Compare Today's Range $5.80 $6.07 50-Day Range $5.27 $9.92 52-Week Range $5.01 $11.48 Volume 169,831 shs Average Volume 347,447 shs Market Capitalization $374.50 million P/E Ratio N/A Dividend Yield N/A Price Target $46.83CMPS Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $50.17 with a high forecast of $120.00 and a low forecast of $21.00. The average price target represents a 832.53% change from the last price of $5.38.

The average Compass stock price prediction forecasts a potential upside of 35.39% from the current COMP share price of $2.43. What is COMP's forecast return on equity (ROE) for 2023-2026? (NYSE: COMP) forecast ROE is N/A, which is considered weak.WebOct 30, 2023 · Nikkei 225. 30,696.96. -0.95%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Compass Pathways PLC (CMPS.OQ) real-time stock quotes, news, price and financial information from ... Real time Compass Pathways Plc (CMPS) stock price quote, stock graph, news & analysis.

Aug 16, 2023 · The private placement is being conducted in accordance with applicable rules of the Nasdaq Stock Market LLC (“Nasdaq”) and was priced to satisfy the “Minimum Price” requirement (as defined ...

Key Points. Cathie Wood is an icon in the world of disruptive tech. Her firm ARK Invest holds positions in Beam Therapeutics, COMPASS Pathways, and 908 Devices. Wall Street analysts have ...10 stocks we like better than Compass Pathways Plc When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor ...CMPS Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $50.17 …In September of 2020, at $17 per share, Compass Pathways stock completed its public offering. Since the initial offering, CMPS has traded as high as $60 per share and seems to average out in the ...

In September of 2020, at $17 per share, Compass Pathways stock completed its public offering. Since the initial offering, CMPS has traded as high as $60 per share and seems to average out in the ...

The Compass Pathways Plc ( CMPS) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $19.09, representing a …

Still, Compass Pathways stock sank 16% in the stock market today. That's after tumbling 12% on Monday from an eight-month high. Compass also reported financial results for the third quarter.The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations....CMPS With so many new IPOs and companies launching in the psychedelic industry it's important to fully evaluate...US20451W1018. Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom. Show more.On another note, COMPASS Pathways has 4 warning signs (and 2 which make us uncomfortable) we think you should know about. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)It is one of the best psychedelic stocks to invest in. On December 15, EF Hutton analyst Elemer Piros initiated coverage of COMPASS Pathways plc (NASDAQ:CMPS) with a Buy rating and a $38 price target.

That's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51% ...COMPASS Pathways has a market cap of $299.3 million, and a 52-week range of $6.74 to $49.52. The stock has a price/book ratio of 1.32, and a price-to-free-cash-flow ratio of -6.9.WebGet a real-time COMPASS Pathways plc (CMPS) stock price quote with breaking news, financials, statistics, charts and more.Summary. BiotechValley Insights is initiating coverage of COMPASS Pathways with a "Bearish" rating at a $13 PT. CMPS has filed an IPO with an initial valuation of US$544M; since then, the stock ...Nov 29, 2023 · About CMPS. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. Oct 22, 2021 · And the biotechnology industry's average price-to-sales multiple is 4.7. Thus, if Compass manages to capture a mere 10% of that per year, it could be bringing in $139 million in revenue. Assuming ...

A high-level overview of COMPASS Pathways plc (CMPS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. News & events. News releases. SEC filings & annual reports. Our annual review. Stock information. Stock quote & chart. Historical price lookup. Corporate governance.Web

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression, and launches new research center. Read more. Compass is a biotechnology company dedicated to accelerating patient access and experience to evidence-based innovation in mental health care.But buying the stock now could leave the door open for potentially massive upside in a few years if it can get COMP360 on the market. 2. Atai Life Sciences. Much like Compass Pathways, Atai Life ...View the latest COMPASS Pathways PLC ADR (CMPS) stock price, news, historical charts, analyst ratings and financial information from WSJ. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Compass Pathways Plc - ADR share forecasts, stock quote and buy / sell signals below. According to present data Compass Pathways Plc - ADR's CMPS shares and potentially its market environment have been in bearish cycle last 12 months (if exists). COMPASS Pathways's market cap is currently ―. The company's EPS TTM is $-1.981; its P/E ratio is -2.86; COMPASS Pathways is scheduled to report earnings on March 4, 2024, and the estimated EPS forecast is $-0.34. See an overview of income statement, balance sheet, and cash flow financials. Dec 22. Sep 22.Stock Price Forecast The 11 analysts offering 12-month price forecasts for Doximity Inc have a median target of 25.00, with a high estimate of 31.00 and a low estimate of 21.00.Latest CMPS News. View. COMPASS Pathways (CMPS, $5.98) entered Downtrend as Momentum indicator drops below 0 level on Nov 30, 2023. Tickeron - Stocks • 3 days ago. Compass Pathways to participate in upcoming Evercore investor conference. Globe Newswire • 10 days ago.WebCOMPASS Pathways (CMPS) Stock Forecast & Price Prediction. Estimation of the future price movement of COMPASS Pathways stock, based on various factors such as …

Stock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

13 มี.ค. 2566 ... Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their 'Buy' rating and US$60 price target for COMPASS Pathways after the ...

Compass Pathways PLC (NASDAQ:CMPS) Compass Pathways PLC. 5.94. Delayed Data. As of Nov 29. -0.04 / -0.67%. Today’s Change. 5.01. Today ||| 52-Week Range.Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data ...Feb 7, 2023 · 3. Compass Pathways. Compass Pathways (CMPS 6.61%) isn't a large holding for Wood. The psychedelic stock makes up less than 1% of her Ark Genomic Revolution ETF's portfolio. However, Compass ... Compare with up to 5 Stocks. On Thursday 11/30/2023 the closing price of the COMPASS Pathways PLC (spons. ADRs) share was $6.20 on NAS. Compared to the opening price on Thursday 11/30/2023 on NAS ...Currently 16 wall-street analysts regularly analyze the financials of Compass Pathways Plc on a frequent basis to provide recommendations along with target share price. 16 analysts offering 12-month price forecasts for Compass Pathways Plc (CMPS) have a share price target of $42.13.WebShares of Compass Pathways PLC pointed north out of the gate, as the first trade was 37.6% above the initial public offering price. The said Friday that it's upsized , above the …See the latest Compass Pathways PLC ADR stock price (CMPS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.And the biotechnology industry's average price-to-sales multiple is 4.7. Thus, if Compass manages to capture a mere 10% of that per year, it could be bringing in $139 million in revenue. Assuming ...

Compass Pathways Plc - ADR Stock Price Forecast, "CMPS" Predictons for2023. Markets; Forecast . Crypto Forecasts; Top 5 Crypto forecasts; Tether Usdt forecast; ... Compass Pathways Plc - ADR Stock Forecast and Price Prognosis Data for 2023 . History; Forecast; Data; Market; Q&A; Comments; Buy CRYPTOWe are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. News & events. News releases; Events; Presentations; SEC filings & annual reports; Our annual review; Stock information. Stock quote & chart; Historical price lookup; Analyst Coverage; Split history; Corporate ...A high-level overview of COMPASS Pathways plc (CMPS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.WebCOMPASS Pathways Stock forecast & analyst price target predictions based on 6 analysts offering 12-months price targets for 5Y6 in the last 3 months.Instagram:https://instagram. wonder wellness gummies reviewspartial real estate investmentmost profitable options strategy1943 still penny Stock Price Forecast. The 9 analysts offering 12-month price forecasts for Compass Inc have a median target of 2.70, with a high estimate of 5.00 and a low estimate of 2.00. The median estimate ... zim. stockbest financial advisors nashville 2 พ.ย. 2566 ... Stock FTCH logo. FTCH · Farfetch Will Not Announce Third Quarter 2023 ... price prior to the financing, and will be exercisable at the election ... armour residential reit dividend CMPS Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $50.17 with a high forecast of $120.00 and a low forecast of $21.00. The average price target represents a 832.53% change from the last price of $5.38.CMPS. COMPASS Pathways plc. 5.83. -0.22. -3.64%. COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to ...The 10 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 33.00, with a high estimate of 120.00 and a low estimate of 19.00. This indicates a potential increase of 254.08% from the last recorded price of 9.32. The consensus among 11 polled investment analysts is to buy stock in Compass Pathways PLC.